查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128377

神經病變疼痛市場規模、佔有率、成長、全球產業分析、區域洞察與預測（2026-2034年）

Neuropathic Pain Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

神經病變疼痛市場的成長要素

全球神經病變疼痛市場預計在2025年達到82.6億美元，並從2026年的88.3億美元成長至2034年的167.8億美元，預測期內複合年成長率（CAGR）為8.35%。這個市場正經歷顯著成長，主要原因是糖尿病、神經病變、帶狀皰疹、化療引起的神經病變以及其他導致慢性神經痛的神經系統疾病的盛行率不斷上升。抗驚厥藥、抗憂鬱症、鴉片類藥物和外用藥物等神經病變疼痛治療​​方法仍是主要的治療選擇。北美在全球市場中佔領先地位，預計到2025年將佔50.66%的市場佔有率，這得益於強大的製藥公司網路、較高的疾病認知度以及持續的產品創新。

市場趨勢

推動神經病變疼痛市場發展的關鍵趨勢之一是加大對新型疼痛管理療法研發的投入。製藥和生技公司正積極進行臨床試驗，以推出更安全、更有效、副作用更少的治療方法。此外，人們對非鴉片類藥物療法、標靶給藥系統和創新神經系統治療方法也越來越感興趣。多家公司正在進行後期臨床試驗，以改善糖尿病神經病變、三叉神經痛和化療引起的神經病變疼痛的治療效果。

市場促進因素

慢性疾病負擔日益加重是神經病變疼痛市場成長要素之一。糖尿病、癌症、多發性硬化症、腎臟病和帶狀皰疹都會顯著增加神經損傷和慢性疼痛的風險。全球糖尿病患者人數的不斷增加以及癌症發生率的上升，使得需要長期管理神經病變疼痛的患者群體日益擴大。

此外，新產品的不斷推出和持續的臨床研究正在加速市場成長。製藥公司不斷推出先進療法，以改善疼痛管理和患者的生活品質。醫療保健意識的提高和神經病變診斷技術的進步也進一步推動了已開發國家和新興市場的發展。

市場限制因素

儘管市場成長強勁，但現有療法相關的副作用限制了神經病變疼痛藥物的廣泛應用。Pregabalin和Gabapentin等藥物可能引起頭暈、嗜睡、口乾、視力障礙、水腫和疲勞，影響患者的藥物順從性。由於這些副作用，許多患者傾向於選擇其他疼痛管理方法，例如植入式醫療設備、神經刺激和外科手術，這可能會阻礙藥物市場的成長。

市場區隔

按藥物類別分類，抗癲癇藥物預計將成為市場成長的主要驅動力，到2026年將佔28.92%的市場佔有率。對Lyrica 、Neurontin、Glarize、Horizo​​nant和Oxtelar XR等用於治療糖尿病神經病變的藥物的強勁需求，將繼續支撐該細分市場的成長。同時，由於新療法的不斷研發，「其他」細分市場預計將實現最快成長。

按應用領域分類，預計到2026年，化療引起的神經病變細分市場將佔全球市場的39.48%，這主要得益於接受化療的癌症患者人數不斷增加。糖尿病性神經病變細分市場預計也將實現強勁成長，這主要歸功於全球糖尿病盛行率的上升以及針對先進治療方法的研究日益增多。

就給藥途徑而言，由於口服藥物易於取得且服用方便，預計到2026年，口服給藥途徑將佔77.15%的市場佔有率。此外，隨著多家公司正在研發用於治療嚴重神經病變疼痛的注射藥物，注射給藥途徑也預計將穩定成長。

按分銷管道分類，預計到2026年，零售藥局將佔全球市場68.61%的佔有率，這主要得益於處方藥和非處方藥的便利取得。此外，受數位醫療普及和宅配服務擴展的推動，線上藥局預計也將實現最快成長。

區域趨勢

預計北美地區2025年市場規模將達41.8億美元，2026年將達45.1億美元。該地區引領全球市場，原因在於主要公司的強大影響力、糖尿病和癌症盛行率的上升以及人們對神經病變疼痛治療​​的高度重視。

在歐洲，預計到 2025 年市場規模將達到 22.8 億美元，到 2026 年將達到 24.2 億美元。糖尿病和癌症病例的增加，加上藥物研發活動的活性化，正在推動全部區域市場持續擴張。

預計亞太地區到 2025 年將達到 10 億美元，到 2026 年將成長到 10.7 億美元。這一成長是由臨床研究的擴大、醫療保健支出的增加、糖尿病患者人數的增加以及中國、日本和印度等國家創新療法的持續發展所推動的。

預計到 2025 年，拉丁美洲市場規模將達到 4.6 億美元，到 2026 年將達到 4.9 億美元。同時，在醫療基礎設施改善和慢性疼痛管理意識提高的推動下，中東和非洲市場預計到 2025 年將達到 3.3 億美元，到 2026 年將達到 3.4 億美元。

主要市場參與者

全球神經病變疼痛市場的主要參與者包括 Almatica、Azurity Pharmaceuticals、輝瑞公司、Viatris 公司、Supernus Pharmaceuticals、諾華公司、Accord Healthcare、Focus Health Group、Amneal Pharmaceuticals LLC、雅培和梯瓦製藥工業有限公司。這些公司透過收購、合作、新產品發布和投資臨床研究，不斷加強其市場地位。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年主要國家/地區神經病變疼痛盛行率
  • 管道分析：按主要公司分類
  • 新產品發布：按主要公司分類
  • 主要產業趨勢（合併、收購、合作等）
  • 新冠疫情對市場的影響

第5章：2021-2034年全球神經病變疼痛市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 抗驚厥藥物
    • 三環抗憂鬱藥物（TCAs）
    • 鴉片類藥物
    • 辣椒素類物質
    • 其他
  • 市場分析、洞察與預測：按應用領域分類
    • 糖尿病神經病變
    • 化療引起的神經病變
    • 坐骨神經神經病變
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美神經病變疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲神經病變疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區神經病變疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 澳洲
    • 中國
    • 印度
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲神經病變疼痛市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東與非洲神經病變疼痛市場分析、洞察與預測

  • 國家
    • 南非
    • GCC
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Almatica
    • Azurity Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Viatris Inc.
    • Supernus Pharmaceuticals, Inc.
    • Novartis AG
    • Accord Healthcare
    • Focus Health Group
    • Amneal Pharmaceuticals LLC
    • Abbott
    • Teva Pharmaceutical Industries Ltd.
Product Code: FBI110546

Growth Factors of neuropathic pain Market

The global neuropathic pain market was valued at USD 8.26 billion in 2025 and is projected to grow from USD 8.83 billion in 2026 to USD 16.78 billion by 2034, registering a CAGR of 8.35% during the forecast period. The market is witnessing significant growth due to the increasing prevalence of diabetes, cancer, shingles, chemotherapy-induced nerve damage, and other neurological disorders that result in chronic nerve pain. Neuropathic pain therapeutics, including anticonvulsants, antidepressants, opioids, and topical medications, remain the primary treatment options. North America dominated the global market with a 50.66% market share in 2025, supported by strong pharmaceutical presence, high disease awareness, and continuous product innovation.

Market Trends

A key trend driving the neuropathic pain market is the growing investment in research and development of novel pain management therapies. Pharmaceutical and biotechnology companies are actively conducting clinical trials to introduce safer and more effective treatments with fewer side effects. The industry is also witnessing increasing interest in non-opioid therapies, targeted drug delivery systems, and innovative neurological treatments. Several companies are advancing late-stage clinical trials to improve therapeutic outcomes for diabetic neuropathy, trigeminal neuralgia, and chemotherapy-induced neuropathic pain.

Market Drivers

The rising burden of chronic diseases is one of the primary growth drivers of the neuropathic pain market. Diabetes, cancer, multiple sclerosis, kidney diseases, and shingles significantly increase the risk of nerve damage and chronic pain. The growing global diabetic population and increasing cancer incidence have resulted in a larger patient pool requiring long-term neuropathic pain management.

Additionally, increasing product launches and ongoing clinical research are accelerating market growth. Pharmaceutical companies continue to introduce advanced therapeutics to improve pain control and patient quality of life. Growing healthcare awareness and improved diagnosis of neuropathic disorders are further supporting market expansion across developed and emerging economies.

Market Restraints

Despite favorable market growth, the widespread use of neuropathic pain medications is limited by the side effects associated with existing therapies. Drugs such as pregabalin and gabapentin may cause dizziness, drowsiness, dry mouth, blurred vision, edema, and fatigue, affecting patient compliance. Due to these adverse effects, many patients prefer alternative pain management approaches, including implantable medical devices, nerve stimulation therapies, and surgical interventions, which may restrain pharmaceutical market growth.

Market Segmentation

Based on drug class, the anticonvulsants segment is expected to dominate the market with a 28.92% share in 2026. The strong demand for drugs such as Lyrica, Neurontin, Gralise, Horizant, and OXTELLAR XR for diabetic neuropathy management continues to support segment growth. Meanwhile, the others segment is anticipated to register the fastest growth due to ongoing development of novel therapeutics.

By application, the chemotherapy-induced neuropathy segment is projected to account for 39.48% of the global market in 2026, driven by the increasing number of cancer patients receiving chemotherapy. The diabetic neuropathy segment is also expected to witness robust growth due to the rising prevalence of diabetes worldwide and increasing research focused on advanced treatment options.

Based on route of administration, the oral segment is expected to hold 77.15% of the market in 2026 owing to the wide availability and convenience of oral medications. The parenteral segment is anticipated to experience healthy growth as companies continue developing injectable therapies for severe neuropathic pain conditions.

By distribution channel, the retail pharmacy segment is projected to capture 68.61% of the global market in 2026, supported by easy access to prescription and over-the-counter medications. Online pharmacies are expected to witness the fastest growth due to increasing digital healthcare adoption and home delivery services.

Regional Insights

North America accounted for USD 4.18 billion in 2025 and is projected to reach USD 4.51 billion in 2026. The region dominates the global market due to the strong presence of leading pharmaceutical companies, growing prevalence of diabetes and cancer, and high awareness regarding neuropathic pain treatment.

Europe generated USD 2.28 billion in 2025 and is expected to reach USD 2.42 billion in 2026. Rising cases of diabetes and cancer, combined with increasing pharmaceutical research activities, continue to drive market expansion across the region.

Asia Pacific reached USD 1.00 billion in 2025 and is projected to grow to USD 1.07 billion in 2026. Growth is supported by expanding clinical research, rising healthcare expenditure, increasing diabetic population, and ongoing development of innovative therapeutics in countries such as China, Japan, and India.

Latin America generated USD 0.46 billion in 2025 and is estimated to reach USD 0.49 billion in 2026, while the Middle East & Africa market stood at USD 0.33 billion in 2025 and is projected to reach USD 0.34 billion in 2026, driven by improving healthcare infrastructure and increasing awareness of chronic pain management.

Key Market Players

Major companies operating in the global neuropathic pain market include Almatica, Azurity Pharmaceuticals, Pfizer Inc., Viatris Inc., Supernus Pharmaceuticals, Novartis AG, Accord Healthcare, Focus Health Group, Amneal Pharmaceuticals LLC, Abbott, and Teva Pharmaceutical Industries Ltd. These companies continue investing in acquisitions, partnerships, product launches, and clinical research to strengthen their market presence.

Key Industry Developments

Recent developments highlight the industry's strong focus on innovation. In May 2024, Lexicon Pharmaceuticals partnered with Medidata for its Phase 2b clinical study of LX9211 for diabetic neuropathy pain. In April 2024, Vertex Pharmaceuticals announced advancements in Suzetrigine, a selective NaV1.8 pain inhibitor for diabetic neuropathy. In September 2023, Azurity Pharmaceuticals acquired Slayback Pharma to strengthen research and development capabilities. Earlier, Novo Nordisk expanded its chronic disease portfolio through the acquisition of BIOCORP, while Almatica Pharma continued expanding its neuropathic pain product portfolio through new antidepressant launches.

Conclusion

The global neuropathic pain market is expected to experience strong growth through 2034, supported by the rising prevalence of diabetes, cancer, neurological disorders, and an aging population. Continuous investment in innovative drug development, expanding clinical trials, and increasing healthcare awareness are expected to create significant growth opportunities. Although medication-related side effects remain a key challenge, the development of safer, targeted, and non-opioid therapies is likely to transform neuropathic pain management and drive long-term market expansion.

Segmentation By Drug Class

  • Anticonvulsants
  • Tricyclic Antidepressants (TCA)
  • Opioids
  • Capsaicinoids
  • Others

By Application

  • Diabetic Neuropathy
  • Chemotherapy Induced Neuropathy
  • Sciatic Neuropathy
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and BY Country/Sub-region)
    • Japan
    • China
    • Australia
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
    • South Africa
    • GCC
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Neuropathic pain - by Key Countries/Sub-regions, 2025
  • 4.2. Pipeline Analysis - by Key Players
  • 4.3. New Product launches - by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anticonvulsants
    • 5.1.2. Tricyclic Antidepressant (TCA)
    • 5.1.3. Opioids
    • 5.1.4. Capsaicinoids
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Diabetic Neuropathy
    • 5.2.2. Chemotherapy Induced Neuropathy
    • 5.2.3. Sciatic Neuropathy
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anticonvulsants
    • 6.1.2. Tricyclic Antidepressant (TCA)
    • 6.1.3. Opioids
    • 6.1.4. Capsaicinoids
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Diabetic Neuropathy
    • 6.2.2. Chemotherapy Induced Neuropathy
    • 6.2.3. Sciatic Neuropathy
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anticonvulsants
    • 7.1.2. Tricyclic Antidepressant (TCA)
    • 7.1.3. Opioids
    • 7.1.4. Capsaicinoids
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Diabetic Neuropathy
    • 7.2.2. Chemotherapy Induced Neuropathy
    • 7.2.3. Sciatic Neuropathy
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anticonvulsants
    • 8.1.2. Tricyclic Antidepressant (TCA)
    • 8.1.3. Opioids
    • 8.1.4. Capsaicinoids
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Diabetic Neuropathy
    • 8.2.2. Chemotherapy Induced Neuropathy
    • 8.2.3. Sciatic Neuropathy
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. Japan
    • 8.5.2. Australia
    • 8.5.3. China
    • 8.5.4. India
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anticonvulsants
    • 9.1.2. Tricyclic Antidepressant (TCA)
    • 9.1.3. Opioids
    • 9.1.4. Capsaicinoids
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Diabetic Neuropathy
    • 9.2.2. Chemotherapy Induced Neuropathy
    • 9.2.3. Sciatic Neuropathy
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Neuropathic Pain Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anticonvulsants
    • 10.1.2. Tricyclic Antidepressant (TCA)
    • 10.1.3. Opioids
    • 10.1.4. Capsaicinoids
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Diabetic Neuropathy
    • 10.2.2. Chemotherapy Induced Neuropathy
    • 10.2.3. Sciatic Neuropathy
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. South Africa
    • 10.5.2. GCC
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Almatica
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Azurity Pharmaceuticals, Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Pfizer Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Viatris Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Supernus Pharmaceuticals, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Novartis AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Accord Healthcare
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Focus Health Group
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Amneal Pharmaceuticals LLC
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Abbott
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Teva Pharmaceutical Industries Ltd.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Neuropathic Pain Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 8: North America Neuropathic Pain Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Neuropathic Pain Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 13: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Neuropathic Pain Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 18: Asia Pacific Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 19: Asia Pacific Neuropathic Pain Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 20: Latin America Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 21: Latin America Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 22: Latin America Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 23: Latin America Neuropathic Pain Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 24: Middle East & Africa Neuropathic Pain Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 25: Middle East & Africa Neuropathic Pain Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 26: Middle East & Africa Neuropathic Pain Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 27: Middle East & Africa Neuropathic Pain Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Neuropathic Pain Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Neuropathic Pain Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Neuropathic Pain Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Neuropathic Pain Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Neuropathic Pain Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 10: North America Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 11: North America Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Neuropathic Pain Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Neuropathic Pain Market Value Share (%), By Country, 2025
  • Figure 17: Europe Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 20: Europe Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 21: Europe Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Neuropathic Pain Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Neuropathic Pain Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 30: Asia Pacific Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 31: Asia Pacific Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Neuropathic Pain Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Neuropathic Pain Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 40: Latin America Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 41: Latin America Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Neuropathic Pain Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Neuropathic Pain Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Neuropathic Pain Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Neuropathic Pain Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Neuropathic Pain Market Value (USD billion), by Application, 2025 & 2034
  • Figure 50: Middle East & Africa Neuropathic Pain Market Value Share (%), by Application, 2025
  • Figure 51: Middle East & Africa Neuropathic Pain Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Neuropathic Pain Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Neuropathic Pain Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Neuropathic Pain Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Neuropathic Pain Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Neuropathic Pain Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Neuropathic Pain Market Share (%), By Company, 2025